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Task Force #4—How Do We
Select Patients for Atherosclerosis Imaging?
Peter W. F. Wilson, MD, Co-Chair, Sidney C. Smith, JR, MD, FACC, Co-Chair,
Roger S. Blumenthal, MD, FACC, Gregory L. Burke, MD, Nathan D. Wong, PHD, FACC
The coronary heart disease (CHD) risk assessment should
begin in the office of the physician or other health care
provider. All adults should undergo a standard assessment
to help predict future CHD risk. The American College of
Cardiology (ACC) and the American Heart Association
(AHA) endorse the global risk assessment based on the
Framingham risk prediction model, which includes the
traditional risk factors of age, gender, smoking, blood
pressure, total and high-density lipoprotein (HDL) choles-
terol. Once the patient’s absolute CHD risk is assessed, the
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physician then determines whether simple reassurance, fur-
ther lifestyle or pharmacologic intervention, or diagnostic
testing may be warranted (1). The goal of additional
noninvasive imaging for atherosclerosis is to improve
identification of individuals at a high or low risk for
CHD (i.e., optimize risk stratification so as few patients
as possible are classified as intermediate risk). This
presumes that such classification can aid physicians in
prescribing a management strategy for prevention, in that
patients assigned into a “high-risk” category will likely
benefit from aggressive risk-factor modification, while
those at low risk will less likely benefit. It is important to
recognize that the outcome of efforts to better detect risk
is dependent upon the effectiveness of the risk reduction
therapies that ensue.
SCHEMA FOR RISK EVALUATION AND UTILITY
Risk of initial CHD is highly related to age, gender, blood
pressure, total cholesterol, HDL cholesterol, diabetes mel-
litus, and cigarette smoking (2). Asymptomatic adults can
be screened for these factors, and the absolute risk for an
initial hard CHD event (defined here as myocardial infarc-
tion [MI] or CHD death) can be estimated. The results
from these equations can be used to develop a schematic for
further testing (Fig. 1). For instance, American guidelines
have currently set less than 6%, 6% to 20%, and greater than
20% risk for CHD over 10 years as low, intermediate, and
high categories, respectively (3). Based on a recent analysis
of the National Health and Nutrition Examination Survey
(NHANES) III data for total CHD risk (including the end
points angina pectoris, MI, or coronary death), approxi-
mately 35% of adults are classified as low risk, about 40% are
at intermediate risk, and 25% are at high risk of CHD
events (4). Because treatment decisions in patients at inter-
mediate risk for CHD can be difficult, further risk stratifi-
cation by noninvasive tests to assess atherosclerotic burden
may be particularly useful within this risk category.
In contrast, the approach to therapy in low risk (reassur-
ance and adherence to healthy lifestyle habits) and high-risk
(treatment as a CHD risk equivalent) individuals is not
likely to substantially change with additional testing.
Whether the intensity of risk factor treatments could be
decreased based upon favorable results on atherosclerosis
imaging in an otherwise high-risk patient is uncertain. This
concept requires clinical validation, but would potentially
carry beneficial implications for cost-effectiveness consider-
ations (Task Force 5).
A demonstration of integrating atherosclerosis imaging
with clinical risk screening from the office-based risk factor
evaluation is shown in Figure 1. The dashed 6% and 20%
lines denote the interval where there is currently the
likelihood that follow-up noninvasive imaging and detec-
tion procedures may be most useful. Should the procedure
not be performed or lack utility, the resulting posterior
probability might be the same or differ only slightly from the
initial probability of disease, as shown by a dark circle on the
identity line of probability. Conversely, the test may be “pos-
itive” or “negative,” altering the risk assessment either up or
down in relation to the initial evaluation. Hypothetical results
are shown for several examples within the interval of 6% to
20% of initial probabilities (1,5). Finally, it is probable that, in
the future, newer risk markers (e.g., C-reactive protein) may be
considered as potentially additive to the Framingham risk score
(6) and even to subclinical atherosclerosis assessments (7) so as
to further refine the risk assessment.
Targeting the utility of noninvasive testing for persons
estimated to be at intermediate CHD risk (6% to 20% over
10 years) offers some advantages. The rationale behind this
approach is that a test with modest marginal utility, such as
a relative risk of 1.50 for a noninvasive test after consideration
of the pretest risk present from the traditional risk factors,
would be expected to demonstrate efficacy as a diagnostic tool.
A large proportion of individuals age 50 to 80 years old are
candidates for this strategy to identify people at intermediate
CHD risk (Fig. 1, Task Force Report 1).
POTENTIAL BENEFITS OF
ATHEROSCLEROSIS SCREENING
A valuable screening test should: a) identify high- and
low-risk groups (e.g., a low proportion of false negative and
false positives) more accurately; b) enhance the identifica-
tion of high-risk individuals; c) result in a favorable impact
on disease outcomes; d) be relatively free of risk; e) be
cost-effective when compared to the current screening
modalities; and f) educate the public concerning atheroscle-
rosis and vascular disease risk (8).
Improved diagnosis. The goal of cardiovascular disease
(CVD) screening is to accurately determine risk early in the
natural history of disease. Adding subclinical disease mark-
ers to traditional CVD risk-factor screening has the poten-
tial to facilitate more appropriate, targeted interventions
that will further reduce CVD morbidity and mortality in
clinical and population-based settings. Various studies have
Figure 1. Serial testing and risk of disease.
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determined that subclinical disease markers of atherosclero-
sis improved the ability to identify the subset of individuals
who are at increased risk for CVD outcomes. Examples of
specific markers that have been shown to provide additional
information beyond traditional CVD risk factors include
ankle brachial index (9,10) and carotid intima-media thick-
ness (IMT) (11–13). For example, based on these data, it is
logical to anticipate that the addition of noninvasive mark-
ers of atherosclerosis may enhance our ability to diagnose
the amount and potential severity of early/asymptomatic
CVD. Other atherosclerosis markers (magnetic resonance
imaging [MRI], coronary artery calcium (CAC), and bra-
chial artery vasoreactivity) appear to have potential but do
not yet have the depth of scientific evidence documenting
their validity, reproducibility, and value in predicting CVD
events beyond risk factors (14–16).
Incremental management impact. A major potential ben-
efit of screening for atherosclerosis is to enhance CVD
prevention strategies. The ability to select higher risk
asymptomatic subsets from the population that would ben-
efit from either an earlier or more aggressive risk factor
intervention strategy is a key advantage of subclinical disease
screening. Theoretically, if these additional markers are
used, preventive measures (lifestyle interventions and/or
pharmacologic interventions) can be implemented earlier in
the course of disease, with the potential not only to reduce
the burden of clinical outcomes but also to reduce subse-
quent subclinical or atherosclerotic disease progression.
Observational data are key to improving management of
vascular disease, but diagnostic imaging utility should also
be tested with randomized clinical trials.
Published studies that used noninvasive CHD risk assess-
ment in this situation have generally not been restricted to
prespecified initial probabilities, and some have been
limited by selection, observer, and publication bias.
Undertaking an experimental design, including blinding
the involved patients and their physicians would allow
rigorous testing of the utility of the new procedures.
Appropriate exclusion criteria within such an experimen-
tal design would be necessary to address concerns over
withholding information for persons with very “abnor-
mal” test results. Alternatively, rigorous analysis of test-
ing strategies in this situation might be undertaken by
randomizing patients to testing or no testing, then
prospectively assessing outcomes.
It is important to frame both the testing schema and the
hypothesis that would be tested. The null hypothesis would
be that the newer noninvasive testing provides no addi-
tional benefit beyond the traditional risk-factor assess-
ment. For example, information from the new diagnostic
procedure would be put into a Cox prediction model that
included a CHD risk estimate score and results for the
new diagnostic test. A statistically significant relation
between the new variable and the outcome in the statis-
tical model would provide evidence of the incremental
utility of the new diagnostic procedure. The noninvasive
test score could be considered in various ways to test the
hypothesis—the data could be as a continuous variable, as
a “positive” test, or as a “negative” test. It is also possible
that the utility of a “negative” test that significantly
decreased the posterior probability of disease would be
helpful in terms of clinical care, as aggressive therapy for
persons with abnormal risk factors but little risk of
disease would be useful information. Important interpre-
tive considerations include both the presence and the
clinical relevance of the observed results.
MATCHING MODALITIES TO
SPECIFIC PATIENT POPULATIONS
Young versus old patients. Assigning the same Framing-
ham Risk Score (FRS) points to all individuals of the same
chronological age does not take into account the great
variation in plaque burden at a given age. More accurate
determinations of risk through measurement of subclinical
atherosclerosis may also be useful in older people as a way to
determine one’s biological age rather than simply one’s
chronological age. The Adult Treatment Panel (ATP) III
pointed out that measurement of coronary calcium may be
useful for older persons in whom traditional risk factors lose
some of their predictive power. A high CAC score may “tip
the balance in favor of a decision to introduce low-density
lipoprotein (LDL)-lowering drugs for primary prevention
in older patients” (17).
No studies have directly compared the accuracy of mul-
tiple imaging modalities for cardiovascular prognosis across
a broad age range of patients. Furthermore, the practicing
physician would optimally seek to couple accurate informa-
tion on cardiovascular risk to a change in management that
appreciably alters that risk. Whereas brachial artery reactiv-
ity testing and MRI are potentially more suited for athero-
sclerosis assessment in younger individuals (Task Force 3) in
whom absolute cardiovascular risk is expected to be rela-
tively low, a shift in management to more vigorous recom-
mendations for lifestyle interventions would be more likely
than an alteration in the use of pharmacologic therapies. In
comparison, CAC detection and carotid ultrasonography
may be best matched to middle-aged and older individuals
where the data related to cardiovascular prognosis are most
robust. Finally, the utility of ankle-brachial index (ABI)
testing may be limited to older patients in whom even
asymptomatic abnormalities could alter the approach to
cardiovascular risk reduction.
Men versus women. No data indicate a clear role for
gender in the selection of atherosclerosis imaging for car-
diovascular risk detection. However, the recognition of
gender differences in the prevalence and severity of abnor-
malities found with individual modalities has importance in
rendering accurate risk prediction. For example, CAC
scores and IMT values are generally lower in women than in
men, although the relative risk attached to an individual test
value may exceed that seen in men. Once women are
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postmenopausal, atherosclerosis imaging in men and
women appears to perform comparably, as shown in a recent
sample from the Framingham Offspring Study. In a strati-
fied sample of 318 men and women with a mean age of 60
years studied with electrocardiogram (ECG)-gated mag-
netic resonance scanning, evidence of aortic atherosclerosis
was present in 38% of the women and 41% of the men. In
both genders the presence of atherosclerotic plaque was
correlated with the Framingham risk score (18). In middle-
aged women, because false positive exercise stress tests are
common, atherosclerosis imaging may be more cost-
effective than traditional noninvasive testing (19).
Ethnic differences in subclinical disease. Carotid ultra-
sonography is predictive of cardiovascular outcomes in both
black and white individuals, although differences in the
extent and location of carotid atherosclerosis varies some-
what by race. In the Cardiovascular Health Study (CHS),
including a limited sample of 244 black adults at least 65
years of age, common carotid walls were thicker and ABI
ratios were lower in blacks of both genders, whereas internal
carotid walls were thinner in black women, after adjusting
for traditional CHD risk factors (20). The relationship
between race and carotid atherosclerosis varies depending
on the site of analysis. For example, in both the Insulin
Resistance Atherosclerosis Study (IRAS) and the ARIC
study, blacks had the same or less atherosclerosis in the
proximal internal carotid artery, yet greater atherosclerosis
at other carotid sites (21). Among Hispanics, atherosclerosis
in the common carotid artery was less severe than that of
whites, after risk-factor adjustment (22). It is unclear
whether the relatively minor quantitative differences in these
measured carotid atherosclerosis values would cause a shift
in the clinical cardiovascular risk assessment and subsequent
cardiovascular management.
The relationships between CAC and race are similarly
complex. Several groups have found that blacks have less
CAC than whites at middle age and older (23–25). In one
study, despite the finding that the prevalence of CAC was
36% in blacks and 60% in whites, black participants sus-
tained more CVD events than did whites during 70 months
of follow-up (23). Few data are available for CAC assess-
ments in other ethnic groups. These data suggest caution in
applying CAC assessments to ethnic minorities until
ethnic-specific outcome studies have been completed.
Diabetes mellitus and renal disease. Although diabetes
mellitus is classified as a CHD risk equivalent and, thus, the
diagnosis of subclinical CHD might not be expected to shift
the management strategy, recent data from Kuller et al. have
challenged this notion (23a). Examining a population of
diabetic subjects in CHS with carotid ultrasonography, the
investigators detected a significant gradient of cardiovascu-
lar risk in diabetics associated with the presence of subclin-
ical atherosclerosis. In that study, the presence of subclinical
atherosclerosis increased the risk for incident CHD by
100%. Similar data are not yet available for other imaging
modalities. In a study of asymptomatic diabetics, no signif-
icant age differences were seen in CAC scores between
women and men (26). This suggests that the premenopausal
protection afforded women in the development of CAC is
lost, and potentially extends the relevance of coronary
calcium scanning to women diabetics of younger age. Thus,
testing for subclinical atherosclerosis, even in a clinical
high-risk group, appears to modulate the coronary risk
assessment. Although such a finding is unlikely to broadly
alter the management of these patients, such data could lead
to increased vigilance on the part of patients and providers
for the warning signs of CHD, particularly in a setting of
limited financial or personnel resources. Similar arguments
potentially apply to patients with end-stage renal disease
(ESRD), another high-risk group for CVD. An elevated
level of coronary calcification is seen in ESRD patients at a
much younger age than in the general population. Even
young adults on dialysis may have rapidly progressive CAC.
Whether the detection of subclinical atherosclerosis in such
high-risk populations can meaningfully direct therapies to
achieve enhanced patient outcomes should be the subject of
clinical trials.
Individuals with a family history of premature CVD.
The FRS does not take into account family history as family
history analysis did not demonstrate sufficient incremental
risk for a family history of premature CHD to be included
in the risk assessment equations. Nevertheless, a large body
of case-control and cohort studies report that a family
history of premature CHD independently predicts CHD
events. These discrepant findings may be due to the way in
which family history was assessed in the various studies. It
appears that the risk for CHD is higher the younger the age
of onset in the affected family member and the greater the
number of affected first-degree relatives (3).
Recently, Valdes et al. (27) reported that CAC was more
prevalent in asymptomatic adults with a positive family
history for premature CHD (male first degree relative less
than 5 years and female less than 65 years). Traditional risk
factors accounted for only 20% to 30% of the variance in
calcium score. This study included only whites; subjects
with diabetes, poorly controlled hypertension, current
smoker, or cholesterol greater than 300 mg/dl were ex-
cluded. A measure of subclinical atherosclerosis such as
coronary calcification determination may be very helpful in
persons with a family history of premature coronary disease,
because this risk factor is not accounted for in the FRS.
POTENTIAL DISADVANTAGES
OF ATHEROSCLEROSIS SCREENING
Screening for atherosclerosis in “real world” settings. It
is important to note that the vast majority of data that
documents the importance of subclinical disease markers to
predict CVD outcome has been collected in highly con-
trolled research settings (28,29). Thus, excellent quality
control measures, very detailed protocols, and highly trained
personnel were involved in all phases of the imaging and
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reading components. Translating the results of clinical
studies to real-world settings will require similar attention to
quality control and accuracy. Without such controls, the
potential exists for misclassification of subclinical disease,
resulting in errors in the cardiovascular risk assessment.
False positives. Definitions of a positive test procedure are
necessarily problematic for a test that is used prognostically
without immediate clinical and pathologic correlation.
Large-scale observational projects, such as the National
Institute of Health (NIH)-sponsored investigation entitled
“Multi-Ethnic Study of Atherosclerosis” (MESA) that is
underway, will address this issue. It is inevitable that any
screening program would have false positives owing to
variability in measurement of subclinical atherosclerosis
(e.g., improper imaging of the carotid artery via ultrasound,
errors in reading, transposition of data). Although the
proportion of false positives would be expected to be
relatively small, the aggregate impact on the number of
misclassified individuals would be increased should a screen-
ing program be implemented on a large scale. The adverse
impact of a false positive test is that individuals will be
unduly alarmed and perhaps would be subjected to a more
aggressive treatment course than would be warranted based
on their “true” risk of CVD.
False negatives. Just as with any screening test, the poten-
tial exists for false negatives. A variety of reasons exist for
not detecting “true” subclinical atherosclerosis. Similar to
the case for false positives, variability in measurement or
reading techniques could also result in classifying an indi-
vidual with atherosclerosis as being disease-free. In addi-
tion, other examples may include being unable to identify a
noncalcified atherosclerotic lesion using a computed tomog-
raphy (CT) scan or when carotid ultrasound focuses on a
specific area of the vascular bed and misses an adjacent area
with a significant plaque. As reported by Detrano et al. (15),
some coronary disease events occur in persons with CAC
scores less than 75 Agatston units, and both physicians and
the public should be aware that CAC evaluations help to
define prognosis but are not definitive. Similarly, IMT
scores in the top quintile were predictive of later CHD in
the CHS cohort, but the overall vascular disease risk in this
cohort was high, and individuals with “negative” tests also
experienced events relatively commonly during follow-up
(13). Individuals should not be given a false sense of security
when a test is “negative,” thereby missing an opportunity to
reduce the burden of atherosclerotic disease by treating a
known risk factor.
Incidental findings. In the process of conducting an as-
sessment for subclinical atherosclerotic disease measures,
there is the potential for the identification of other inciden-
tal findings (either nonatherosclerotic or non-CVD find-
ings). For example, when noncoronary pathology in the field
of view is assessed in studies using CT scanning to screen
for CAC, approximately 20% of participants have other
findings (ranging from benign calcified nodules to undiag-
nosed lung cancer). Although identification of asymptom-
atic disease may be of benefit to some individuals, a substantial
burden is placed on these participants and their health care
providers to determine if additional diagnostic tests or treat-
ment are required. Thus, these incidental findings may result in
increased health care costs to rule out other disease processes
and may cause undue anxiety on an individual basis. Detection
of incidental findings is much less frequent for some other
subclinical atherosclerosis modalities (i.e., ABI, carotid IMT,
brachial artery endothelial function) in which imaging is
limited to a specific vascular bed location.
Effects on insurability. Clinical events certainly impact on
both an individual’s long-term prognosis and their cost of
obtaining insurance. Subclinical disease is highly related to
the potential for the development of CVD events and should
be considered a modifiable factor. It remains unclear how
data collected in a subclinical atherosclerosis screening
program would be used by actuaries in underwriting life
insurance and individual health insurance policies. Norma-
tive data for IMT, MRI, ABI, and CAC have not been
scrupulously developed with the same degree of accuracy
and precision as some other diagnostic testing, such as
cholesterol and blood pressure measurement. Knowing
more about individual CVD risk can be beneficial to an
individual’s health, but the question remains as to whether
collection of these data on a high-risk individual will
increase the person’s cost of obtaining insurance.
Other considerations. When considering the risk benefit
of subclinical atherosclerosis screening, it is important to
state that CAC assessment using CT involves exposure to
ionizing radiation. Although discovery of subclinical ath-
erosclerosis in the coronary bed may change the CVD
treatment strategy and be a valuable addition to an individ-
ual’s care, the radiation exposure from this test should be
considered as we determine the appropriateness of using this
test in low-risk individuals or as part of a nationwide screening
program. Finally, cost is a major consideration of screening,
and that topic is discussed in the Task Force 5 report.
HOW SHOULD TESTS BE ACCESSED?
Benefit and harm of self-referral for noninvasive testing
for atherosclerosis. Access to noninvasive testing varies
greatly and depends on the type of test and the extent to
which the test is available and commercialized. The concern
of self-referral access to atherosclerosis imaging is for a
patient to be either falsely reassured if the result is negative,
despite significant risk factors, or needlessly alarmed with a
result that could be very common and may not pose
immediate risk.
Despite convincing evidence from population-based
studies showing increased ABI to predict a wide range of
cardiovascular end points, few physicians currently use ABI
in clinical screening, and the financial incentives have not
been established. This may be partly due to the absence of
advertising and commercialization of this test, which limits
its current use to primarily a research tool and not to
1902 Wilson and Smith Jr et al. JACC Vol. 41, No. 11, 2003
Task Force #4—Selecting Patients for Atherosclerosis Imaging June 4, 2003:1855–917
widespread use as a self-referred test by the public. The
relatively low cost of equipment and performance of the
required measures for determination of ABI, and its ability
to detect subclinical peripheral arterial disease, suggest there
may be benefit for self-referral in certain populations at
potential risk, such as persons aged 50 years and over or
those with multiple risk factors (1).
Magnetic resonance imaging of atherosclerotic plaque has
great promise to noninvasively image the high-risk vulner-
able plaque and allow serial evaluation of the progression/
regression of atherosclerosis (30). At this time, the proce-
dure is limited in availability and is used almost exclusively
as a research tool. The expense and complexity of acquisi-
tion and interpretation limit this technology to a few
research sites, suggesting self-referral is not appropriate at
this time.
Carotid ultrasonography of IMT has been advertised in
the form of “stroke screening,” with testing often being done
in the form of mobile test teams. Although carotid IMT has
clearly been shown to be associated with risk of cardiovas-
cular events and stroke in large-scale population-based
studies, guidelines do not exist to recommend specific
follow-up above certain age- and gender-based cut points
for IMT, nor how these recommendations may be modified
according to an individual’s cardiovascular risk factor profile.
In addition, the reproducibility of the measurement may be
in question unless done at a highly skilled facility.
The success of numerous CT scanning centers has de-
pended on self-referred asymptomatic patients, often with
one or fewer risk factors, as a result of mass media
advertising campaigns, despite the insistence by many phy-
sicians, including those overseeing such centers, that phy-
sician referral of persons with multiple risk factors is the
most appropriate way to access the technology. In addition,
although some centers have taken the initiative to provide
one-on-one physician consultations that attempt to explain
clearly the meaning of the results, this is not the typical
practice. Some evidence suggests that patients with a posi-
tive scan may worry more and seek consultation with their
physician, but may also try to lose weight, start a low-fat
diet, or possibly comply better with cholesterol-lowering or
blood pressure-lowering medicine (31). Although most of
these could be construed as benefits, a potential disadvan-
tage results from patients who have a negative scan, believ-
ing perhaps less determined to undertake healthful lifestyle
changes or to comply with physician orders. The additive
management impact of these tests has not yet been com-
pletely defined by rigorous clinical trials.
Does an abnormal atherosclerosis imaging test shift
management to a secondary prevention strategy? Primary
prevention efforts for individuals with multiple risk factors
may be considered insufficient when their cumulative risk is
high enough that it is similar to patients with existing
vascular disease. The Third Adult Treatment Panel of the
National Cholesterol Education Program (ATP III, 2001)
extended previous guidelines in recommending that those
with two or more risk factors whose calculated 10-year risk
of CHD exceeded 20%, or if diabetes, peripheral arterial, or
symptomatic carotid disease were present, be treated as a
CHD risk equivalent. Following this paradigm, the pres-
ence of a sufficient burden of subclinical vascular disease
could be construed as CHD risk equivalent when the additive
risk of conventional risk factors (including patient age) and
atherosclerosis burden exceeds the 2% annual threshold. In
general, these threshold values require better definition for all
modalities of subclinical atherosclerosis testing. However,
among available modalities, sufficient evidence exists to recom-
mend persons with peripheral vascular disease diagnosed by an
ABI below 0.90 to be candidates for secondary prevention
management. In such individuals, relative risks are similar to
those seen in secondary prevention, considered a justification
for moving a patient with apparent “intermediate risk” based
on office risk assessment to high-risk status (1).
In the case of carotid ultrasound assessment of carotid
IMT, epidemiologic data show significantly increased car-
diovascular event risk among those with IMT of 1 mm or
greater, or for persons in the highest quintile of IMT (32).
Relative risks similar to that seen in secondary prevention
have also justified that such individuals who would other-
wise be considered intermediate risk should be elevated to a
“coronary risk equivalent” (1). Moreover, such persons may
be at greater risk of stroke than many of those whose
10-year CHD risk is estimated to be 20% or more, but who
may not have increased IMT.
Currently, MRI can quantitate plaque burden in periph-
eral arterial beds (i.e., aorta and carotid), and it has the
unique, but unproven, potential to morphologically charac-
terize the vulnerability of atherosclerosis (30). However,
absent large population-based data on MRI of atherosclerosis,
including how such findings may relate to clinical events, no
recommendations have been made as to whether persons with
identified plaque (and to what extent) should be candidates for
secondary prevention, although as such data accumulate in the
future, experts may make such recommendations.
Efforts to use results from noninvasive testing for the
purposes of risk stratification have been perhaps most active
with coronary calcium imaging by CT. Rumberger et al.
(33) first published guidelines recommending more aggres-
sive risk factor modification efforts for persons with coro-
nary calcium scores exceeding 400. Others have suggested
that anyone with calcium scores at or above the 75th
percentile, associated with substantially increased relative
risks, to be candidates for treatment according to secondary
prevention guidelines. Despite the lack of consistent recom-
mendations, the current practice by numerous physicians is
to consider a significant calcium score to warrant athero-
sclerosis that must be treated aggressively, as in the case of
a person with known coronary artery disease (CAD).
However, it will be several years before the results of the
NIH-sponsored MESA are published. This study investi-
gates the incremental value of CT coronary calcium scores
for prediction of cardiovascular events over both standard
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and novel coronary risk factors. Data from other cohorts
(34,35) as well as a recent meta-analysis from earlier studies
(36), and other reports documenting significant calcium
scores to signify clinically significant atherosclerosis, suggest
the use of high calcium scores (400 or higher, or at or above
the 75th percentile for age and gender) may be reasonable,
among intermediate risk individuals (e.g., those with a
premature family history of CHD or risk factors achieving
at least a 10% risk of CHD over 10 years), to warrant
aggressive treatment as a CHD risk equivalent.
The role of serial testing. Serial testing for evidence of
subclinical atherosclerosis using coronary CT scanning
(30,37) and other more experimental techniques (30) has
been identified as an opportunity to study and track arterial
changes in patients on medical therapies. Serial evaluation
of coronary calcium by CT has been limited to studies from
self-referred or clinical cohorts, where annual progression
rates of 22% to 52% have been reported, with a wide range
of interscan reproducibility (37). The highly variable esti-
mates of CAC within individual patients, particularly if
calcium scores are low, raises questions regarding the utility
of serial scanning to track atherosclerotic disease. Ongoing
observational and randomized clinical trials will help estab-
lish the validity of serial coronary calcium scanning as a
surrogate measure of atherosclerosis risk and to test whether
changes in CAC severity translate into an altered risk of
coronary disease risk assessment.
The use of serial carotid ultrasonography for tracking of
IMT has perhaps the strongest evidence base. Numerous
clinical trials have documented the effect of treating dyslip-
idemia, blood pressure, and other risk factors to slow
progression of IMT. Moreover, studies have also shown risk
factor levels associated with progression of carotid IMT (38)
to be greater in persons with, versus without, coronary artery
disease (39), and in those with new coronary events (40).
Despite these data, serial evaluation of carotid IMT is not
widely used clinically, nor are widespread recommendations
regarding the appropriateness and time frame for repeated
assessments in either asymptomatic or symptomatic indi-
viduals. Moreover, should repeated carotid ultrasonography
be performed, it is essential that such repeat scans be read by
research-quality laboratories to ensure standardization. Such
laboratories are not widely available in the U.S.
Cardiovascular MRI has great future potential as a means
to track the progression of overall atherosclerotic plaque
burden. One recently published clinical trial (41) showed
significant reductions in atheroma plaque cross-sectional
area resulting from simvastatin therapy over a treatment
period of only 12 months.
For serial testing of atherosclerotic imaging modalities to
be practical, such evaluations: 1) should be standardized to
ensure accurate determination of change/progression, as-
sessed by research-quality laboratories; 2) should be suffi-
ciently reproducible—e.g., change deemed to be clinically
significant should be substantially greater than intertest
measurement error; and 3) there should be agreed-upon
guidelines for more aggressive clinical management based
on a known degree of progression. Although standardiza-
tion of measurements can be acceptable and sufficiently
reproducible for several of the imaging technologies, there is
wide variation and great dependency on which laboratory is
used, as well as in reading or evaluating images. Although
more aggressive treatment might be recommended for those
demonstrating progression of atherosclerosis, specific guide-
lines do not exist, in part because there are no currently
agreed-upon criteria used to define clinically significant pro-
gression of disease for any of the imaging modalities reviewed
in this report. Until then, however, routine serial testing of any
imaging modality in patients receiving assessments of nonin-
vasive testing of atherosclerosis is not recommended.
When is further testing (e.g., stress testing, invasive
testing) required after atherosclerosis imaging? In the
above-noted guidelines first published by Rumberger et al.
(33), potential further testing was suggested for persons
with coronary calcium scores exceeding 400. More recently,
Berman et al. (42) have recommended the use of coronary
calcium screening in persons with a low-to-intermediate
(0.15 to 0.50) pretest likelihood of CAD, and when scores
are in the range of 100 to 400, recommending treatment
according to AHA secondary prevention guidelines; for
those with a score of 400 or greater, they suggest direct
referral to a stress nuclear test. One preliminary report
showed nearly half of those with a score of 400 or greater to
demonstrate a positive nuclear scan test, although these
persons who were tested both with a myocardial perfusion
single-photon emission computed tomography (SPECT)
test and electron-beam CT scanning for coronary calcium
had other indications for nuclear testing, resulting in their
referral (43). No guidelines exist for direct referral to
coronary angiography or other invasive testing given a
particular calcium score. In addition, no clear cut points
exist for other atherosclerosis imaging modalities for referral
to further diagnostic testing. It is clear that many variables
determine whether a patient should be referred for further
noninvasive or invasive diagnostic testing, such as medical
history, presence, and extent of any current symptoms, as
well as existence of other risk factors. Physicians should
carefully evaluate these criteria in combination with the
results from any atherosclerosis imaging tests in making a
prudent decision as to the need and type of additional
diagnostic testing.
Integrating clinical and atherosclerosis screening.
Information obtained from noninvasive imaging of athero-
sclerosis can be valuable in refining risk-stratification efforts,
particularly for intermediate-risk patients, which could
comprise as much as 40% of the U.S. adult population (1).
It is of interest to note that the 1999 AHA Prevention V
Conference considered persons aged 50 or older or those at
intermediate or higher risk of CHD to be possible candi-
dates for ABI assessment or carotid B-mode ultrasonogra-
phy. Specialized screening could possibly provide incremen-
tal value over standard risk factors in asymptomatic persons,
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justifying such use in an intermediate risk group. Algo-
rithms have been proposed that use a Framingham risk
score and arterial calcification and then the “age points” in
the Framingham risk algorithm, based on the extent of
coronary calcium (subtracting points if coronary calcium
score is below the 25th percentile for age and gender and
adding points if the score exceeds the 75th percentile) (44).
Although this approach is reasonable, its validity has not yet
been demonstrated. Rather, an individualized approach
with respect to enhancing risk level in the presence of
significant atherosclerosis detected from imaging techniques
seems prudent at this time. A decision for atherosclerosis
imaging should be based on physician recommendation and
referral, but only after a careful consideration of known
medical history and evaluation of major standard cardiovas-
cular risk factors by office-based techniques.
FUTURE DIRECTIONS
1. Selecting intermediate risk patients for screening with
plaque burden assessment has potential theoretical ad-
vantages within a Bayesian approach to screening. More
study is needed in low- and high-risk patients.
2. Once a modality is shown to incrementally predict
cardiovascular risk, then effectiveness studies that estab-
lish threshold values (indicating a shift to increased
intensity of risk factor treatments) are appropriate.
3. Once selected for atherosclerosis imaging, patients re-
quire full and appropriate risk-reduction treatments. It is
important to recognize that the outcome of efforts to better
detect CHD risk are ultimately dependent upon the effec-
tiveness of the risk-reduction therapies that ensue.
4. A policy of self referral to atherosclerosis imaging tests is
premature and should be the subject of formal effective-
ness study prior to widespread adoption of this practice.
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Atherosclerosis Imaging Cost Effective?
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In the U.S., an estimated 40 million noninvasive cardiac
tests are performed annually, and this rate has been increas-
ing by as much as 20% per year (1). This growth is part of
a larger trend of progressive annual increases in total U.S.
spending on medical care, which has accelerated over the
past four years. Rising costs of care reflect both an increase
in the prevalence of disease due to aging of the population
and the development of expensive new diagnostic and
therapeutic technologies for cardiovascular disease. For
cardiologists, cardiac imaging encompasses approximately
30% of all Medicare reimbursement, totaling over $1 billion
in 2000 (2). In the area of atherosclerosis imaging, proce-
dural volume for computed tomography (CT) and mag-
netic resonance imaging (MRI) was 555,652 and 719,329
scans, respectively, in the year 2000 (Siemens Medical
Engineering Group, Magnetic Resonance Division, Ise-
lin, New Jersey), whereas 1999 Medicare utilization of
carotid or peripheral extremity studies was 424,978 (2).
Although no reliable statistics exist on the use of diagnostic
tests to detect asymptomatic atherosclerosis, estimates on the
use of electron beam tomography (EBT) suggest that approx-
imately 300,000 scans are performed annually in 79 centers in
the U.S. (personal communication, Leslee J. Shaw, 2002).
Thus, diagnostic cardiovascular tests are not only a significant
part of modern cardiovascular care; they are also a “big
business.” The economics of this testing, therefore, is of
importance for both clinicians and policymakers.
Economic evaluations, particularly cost-effectiveness analy-
ses, are not simply concerned with costs. Instead, these analyses
combine cost information with relevant clinical outcome data
to provide a measure of the value of a new technology in
relation to relevant alternatives. Unfortunately, very few pub-
lished economic evaluations of atherosclerosis imaging tech-
niques exist (3–9). Two major reasons for this deficiency
can be postulated. First, many of the technological
advances in cardiac imaging were introduced without
undergoing rigorous scientific testing on effectiveness.
Without adequate effectiveness data, economic evalua-
tion is extremely limited. Second, economic analyses are
most straightforward when evaluating therapies that save
lives or improve quality of life. Assessing the value of
tests that incrementally improve a diagnosis or an assess-
ment of prognosis, which may or may not alter outcome,
is more difficult and often yields less persuasive results.
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